Antidepressants and mood stabilizers (e.g., SSRIs, mirtazapine, lithium): Some are associated with increased appetite or changes in metabolism over time
Hepatic dysfunction
Study Finds Diabetes Medication Reduces Risk Of Death And Heart Disease In People With Arthritis August 12, 2024 (Vancouver) A study conducted by Arthritis Research Canada has revealed that certain diabetes medications, specifically glucagon-like peptide-1 receptor agonists (GLP-1-RAs) like semaglutide (Ozempic), reduced the risk of death and heart attacks in people with immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis, psoriasis, and lupus, who also have type 2 diabetes
State rainy day fund capacity is also beginning to decline following all-time highs, though funds remain stronger than before the pandemic
Federal regulators have approved a new diabetes drug that reduces blood-sugar levels and also helps people lose significant weight
For example, a patient doing well on a GLP-1 therapy may later benefit from a switch to a dual agonist such as tirzepatide if metabolic needs evolve
